胞外体治疗药市场:各标的适应症，各治疗领域，各製剂类型，各给药途径，各地区:产业趋势与全球预测，2022年～2035年

本报告提供全球胞外体治疗药市场相关调查，市场概要，以及各标的适应症，各治疗领域，各製剂类型，各给药途径，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 摘要整理

第3章 简介

• 胞外体概要
• 胞外体生物合成
• 胞外体的应用
• 胞外体治疗药的结构
• 胞外体治疗药的优点
• 胞外体治疗药伴随的风险与未来展望

第4章 胞外体治疗药:市场形势

• 分析调查手法主要的参数
• 胞外体治疗药市场形势
• 胞外体治疗药开发商

第5章 胞外体治疗药的开发商:企业简介

• Codiak BioSciences
• Coya Therapeutics
• Curexsys
• EV Therapeutics
• Evox Therapeutics
• SHIFTBIO

第6章 胞外体疗法:药物简介

• AEGLE Therapeutics
• AVEM Healthcare
• Cellular Biomedicine Group
• OBCTCD24
• ReNeuron
• Stem Cell Medicine

第7章 临床试验分析

第8章 学术津贴的分析

第9章 世界活动分析

第10章 伙伴关係和合作

第11章 资金筹措投资分析

第12章 Start-Ups健康指数

第13章 案例研究:胞外体开发及製造服务供应商

第14章 药物的失败的分析

第15章 市场规模机会分析

• 预测调查手法主要的假设
• 全球胞外体治疗药市场，2027年～2035年
• 全球胞外体治疗药市场，2027年～2035年:各标的适应症
• 全球胞外体治疗药市场，2027年～2035年:各治疗领域
• 全球胞外体治疗药市场，2027年～2035年:各给药途径
• 全球胞外体治疗药市场，2027年～2035年:各製剂类型
• 全球胞外体治疗药市场，2027年～2035年:各地区
• 魅力和竞争力的矩阵

第16章 执行见解

第17章 附录1:表格形式的资料

第18章 附录2:公司及组织的清单

INTRODUCTION

In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Currently, both industry and non-industry players are attempting to develop exosome-based therapeutics for disease management, some of which are already in clinical trials. Moreover, post the onset of the COVID-19 pandemic, there has been a steady increase in the investigational new drug (IND) applications filed for exosome therapies. In a recent review of more than 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use, the exosomes demonstrated benefits in more than 70% of studies.

Q1. What is the current market landscape and recent trends in the exosome therapeutics domain?

The exosome therapeutics market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry. At present, the pipeline features close to 120 therapeutic candidates, and this number is anticipated to grow further in the foreseen future. More than 40% of the total number of drugs are in clinical stage of development. Further, around 30% of the exosome therapeutics are being developed against oncological indications. It is also worth highlighting that, in the last five years, capital investments worth around USD 500 million have been made by strategic investors for the research and development of exosome therapeutics. Additionally, over time, more than 60 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective exosome therapies against multiple target indications. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being evaluated in the advanced clinical stages of development. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the efforts in research and development of various pipeline candidates, over the past decade.

Q3. What are the key challenges faced in the exosome therapeutics domain?

Despite the numerous benefits offered by exosome therapies, developers often face concerns related to the weak therapy preparations, bacterial infections, and contamination with non-exosomal components. Additionally, the heterogeneous nature of such extracellular vesicles (Evs) is one of the major challenges faced during the quantification and characterization of the required Evs from a diverse population of cells. In order to mitigate the aforementioned challenges, novel technologies are being adopted by several stakeholders.

Q4. What are the key value drivers in the exosome therapeutics market?

The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of such therapeutics. Moreover, the growth potential in the emerging economies bolsters the exosome therapeutics market growth.

Q6. How is the revenue generation potential, associated with exosome therapeutics market likely to evolve in the coming years?

The exosome therapeutics market is projected to grow at a CAGR of more than 30%, with anticipated release of a number of therapies in the foreseen future. In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intravenous administration. Further, in terms of therapeutic area, majority share of the revenues is expected to be generated by infectious diseases. Specifically, in terms of geography, the exosome therapeutics market in North America is likely to grow at a significant pace, in the long term.

Q7. Who are the key players engaged in the exosome therapeutics market?

The key players engaged in this domain (which have also been capture in this report) include Cellular Biomedicine Group, Codiak BioSciences, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO.

SCOPE OF THE REPORT

The "Exosome Therapeutics Market by Distribution by Target Indication (COVID-19 Disease, Degenerative Meniscal Injury and Retinitis Pigmentosa), Therapeutic Area (Infectious Diseases, Musculoskeletal Disorders and Ophthalmic Diseases), Type of Formulation (Liquid and Aerosol), Route of Administration (Inhalation, Intravenous, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, Industry Trends and Global Forecasts, 2022-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

• General introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, it provides information on the development process of exosomes and details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.

• A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication (s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious diseases, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.

• Elaborate profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.

• Elaborate drug profiles of the key therapeutics in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.

• A detailed analysis of completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age group of the patients enrolled, active industry and non-industry players and location of the trials.

• An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).

• A detailed analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participants, and active speakers (in terms of number of events).

• An analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant deals.

• A detailed analysis of the various investments made since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in companies focused on the development of exosome therapeutics.

• An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.

• A case study highlighting the companies engaged in offering exosome development and manufacturing services along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).

• An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with exosome therapies market in the mid to long term. Based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2027-2035. Our year wise projections of the current and forecasted opportunity within the exosome therapies market have further been segmented across target disease indication(s) (COVID-19, degenerative meniscal injury and retinitis pigmentosa), therapeutic area (infectious diseases, ophthalmic diseases and musculoskeletal disorders), route of administration (intravenous, intra-ocular, intra-articular and inhalation), type of formulation (liquid and aerosol), geography (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

• Xavier Avat (Chief Business Officer, Capricor Therapeutics)

• Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics)

• Soonho Song (Chief Business Officer, ILIAS Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

• Who are the leading industry and non-industry players engaged in the development of exosome therapies?

• Which are the key drugs being developed across early and late stages of development?

• What are the key agenda items being discussed in various global events / conferences related to exosomes?

• What kind of partnership models are commonly adopted by industry stakeholders?

• Which are the leading funding institutes / centers supporting the research related to exosome therapies?

• Which geographies are the most active in conducting clinical trials related to exosome therapies?

• How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of exosome therapeutics market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, the chapter provides information on the development process of exosomes. Further, the chapter presents details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.

Chapter 4 provides an overview of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication(s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious disorders, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, the chapter provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.

Chapter 5 includes detailed profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.

Chapter 6 includes detailed drug profiles of the key therapeutics in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.

Chapter 7 provides information on completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.

Chapter 8 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).

Chapter 9 features an analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events).

Chapter 10 features an analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant type of deals.

Chapter 11 presents a review of the funding and investments in this domain since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in the companies focused on the development of exosome therapeutics.

Chapter 12 presents an analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.

Chapter 13 includes information on more than 45 exosome service providers that are currently offering services related to development and manufacturing exosomes, and a detailed analysis based on several parameters, such as types of service(s) offered, method of isolation, method of purification, method of characterization, method of exosome manufacturing, scale of operation and scalability. In addition, it provides details on the companies along with information on their year of establishment, company size and location of headquarters.

Chapter 14 provides a detailed analysis focused on exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor

Chapter 15 presents an insightful market forecast analysis, highlighting the likely growth of exosome therapeutics market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across target disease indications (COVID-19 Disease, degenerative meniscal injury and retinitis pigmentosa), therapeutic areas (infectious diseases, musculoskeletal disorders and ophthalmic diseases), routes of administration (inhalation, intravenous, intra-articular and intra-ocular), types of formulations (liquid and aerosol), and geography (North America, Europe and Asia-Pacific and Rest of the World).

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented details of interviews held with (in alphabetical order of company / organization names) Xavier Avat (Chief Business Officer, Capricor Therapeutics), Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics) and Soonho Song (Chief Business Officer, ILIAS Biologics)

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2 Market Segmentation
• 1.3. Research Methodology
• 1.4. Key Questions Answered
• 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Overview of Exosomes
  • 3.1.1. Types of Extracellular Vesicles
  • 3.1.1. Potential Sources of Exosomes
• 3.2. Exosome Biogenesis
  • 3.2.1. Exosome Formation and Development Process
  • 3.2.2. Secretion of Exosomes
• 3.3. Applications of Exosomes
• 3.4. Mechanism of Exosome Therapy
  • 3.4.1. Exosome Drug Therapy
  • 3.4.2. Exosome RNAi Therapy
  • 3.4.3. Exosome Immunotherapy
• 3.5. Advantages of Exosome Therapies
• 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

• 4.1. Analysis Methodology and Key Parameters
• 4.2. Exosome Therapeutics Market Landscape
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Technology Platform
  • 4.2.3. Analysis by Type of Payload
  • 4.2.4. Analysis by Type of Formulation
  • 4.2.5. Analysis by Type of Therapy
  • 4.2.6. Analysis by Derived Source
  • 4.2.7. Analysis by Target Disease Indication(s)
  • 4.2.8. Analysis by Therapeutic Area
  • 4.2.9. Analysis by Phase of Development and Therapeutic Area
  • 4.2.10. Analysis by Route of Administration
  • 4.2.11. Analysis by Therapeutic Area and Route of Administration
  • 4.2.12. Analysis by Type of Therapy (By Method of Composition)
  • 4.2.13. Analysis by Line of Treatment
  • 4.2.14. Analysis by Dosing Frequency
• 4.3. Exosome Therapeutics Developers
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters
  • 4.3.4. Most Active Players: Analysis by Number of Therapeutics

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

• 5.1. Codiak BioSciences
  • 5.1.1. Company Overview
  • 5.1.2. Product Portfolio
  • 5.1.3. Clinical Trial Information
  • 5.1.4. Recent Developments and Future Outlook
• 5.2. Coya Therapeutics
  • 5.2.1. Company Overview
  • 5.2.2. Product Portfolio
  • 5.2.3. Recent Developments and Future Outlook
• 5.3. Curexsys
  • 5.3.1. Company Overview
  • 5.3.2. Product Portfolio
  • 5.3.3. Recent Developments and Future Outlook
• 5.4. EV Therapeutics
  • 5.4.1. Company Overview
  • 5.4.2. Product Portfolio
  • 5.4.3. Recent Developments and Future Outlook
• 5.5. Evox Therapeutics
  • 5.5.1. Company Overview
  • 5.5.2. Product Portfolio
  • 5.5.3. Recent Developments and Future Outlook
• 5.6. SHIFTBIO
  • 5.6.1. Company Overview
  • 5.6.2. Product Portfolio
  • 5.6.3. Recent Developments and Future Outlook

6. EXOSOME THERAPEUTICS: DRUG PROFILES

• 6.1. AEGLE Therapeutics
  • 6.1.1. Company Overview
  • 6.1.2. AGLE-102: Product Portfolio
    • 6.1.2.1. AGLE-102: Clinical Trial Information
  • 6.1.3. Recent Developments and Future Outlook
• 6.2. AVEM Healthcare
  • 6.2.1. Company Overview
  • 6.2.2. Ardoxso: Product Portfolio
    • 6.2.2.1. Ardoxso: Clinical Trial Information
  • 6.2.3. Recent Developments and Future Outlook
• 6.3. Cellular Biomedicine Group
  • 6.3.1. Company Overview
  • 6.3.2. Financial Information
  • 6.3.3. haMPC-Exos: Product Portfolio
    • 6.3.3.1. haMPC-Exos: Clinical Trial Information
  • 6.3.4. hMSC-Exos: Product Portfolio
    • 6.3.4.1. hMSC-Exos: Clinical Trial Information
  • 6.3.5. Undisclosed Drug 1: Product Portfolio
    • 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
  • 6.3.6. Recent Developments and Future Outlook
• 6.4. OBCTCD24
  • 6.4.1. Company Overview
  • 6.4.2. CovenD24: Product Portfolio
    • 6.4.2.1. CovenD24: Clinical Trial Information
  • 6.4.3. Recent Developments and Future Outlook
• 6.5. ReNeuron
  • 6.5.1. Company Overview
  • 6.5.2. Financial Information
  • 6.5.3. Undisclosed Drug 1: Product Portfolio
    • 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Stem Cell Medicine
  • 6.6.1. Company Overview
  • 6.6.2. Undisclosed Drug 1: Product Portfolio
  • 6.6.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

• 7.1. Analysis Methodology and Key Parameters
• 7.2. Exosome Therapeutics: List of Clinical Trials
  • 7.2.1. Analysis by Trial Status
  • 7.2.2. Analysis by Trial Registration Year
  • 7.2.3. Analysis by Type of Sponsor / Collaborator
  • 7.2.4. Analysis by Registration Year and Type of Study
  • 7.2.5. Analysis by Registration Year and Status of Trial
  • 7.2.6. Analysis by Study Design
  • 7.2.7. Analysis by Patient Enrollment
  • 7.2.8. Year-wise Trend of Completed and Recruiting Trials
  • 7.2.9. Analysis by Age Category
  • 7.2.10. Analysis by Phase of Development and Trial Status
  • 7.2.11. Analysis by Phase of Development and Patient Enrollment
  • 7.2.12. Most Active Industry Players: Analysis by Number of Registered Trials
  • 7.2.13. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 7.2.14. Analysis by Trial Location
  • 7.2.15. Analysis by Trial Status and Geography

8. ACADEMIC GRANT ANALYSIS

• 8.1. Analysis Methodology and Key Parameters
• 8.2. Exosome Therapeutics: List of Academic Grants
• 8.3. Analysis by Year of Grants Awarded
• 8.4. Analysis by Amount Awarded
• 8.5. Popular NIH Departments: Analysis by Number of Grants
• 8.6. Analysis by Type of Funding Institute Center
• 8.7. Analysis by Support Period
• 8.8. Analysis by Purpose of Grants
• 8.9. Word Cloud Analysis: Emerging Focus Area
• 8.10. Analysis by Grant Activity Code
• 8.11. Analysis by Local Recipients
• 8.12. Analysis by Type of Recipient Organization
• 8.13. Popular Recipient Organizations: Analysis by Amount Awarded
• 8.14. Popular Recipient Organizations: Analysis by Number of Grants
• 8.15. Analysis by Study Section Involved
• 8.16. Analysis by Type of Grant Application
• 8.17. Analysis by Funding Institute Center and Support Year

9. GLOBAL EVENT ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. List of Global Events Related to Exosomes
  • 9.3.1. Analysis by Year of Event
  • 9.3.2. Analysis by Event Platform
  • 9.3.3. Analysis by Type of Event
  • 9.3.4. Analysis by Location of Event
  • 9.3.5. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
  • 9.3.6. Most Active Organizers: Analysis by Number of Events
  • 9.3.7. Most Active Industry Participants: Analysis by Number of Events
  • 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
  • 9.3.9. Analysis by Designation of Participant
  • 9.3.10. Analysis by Affiliated Department of Participant
  • 9.3.11. Most Active Speakers: Analysis by Number of Events

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Exosome Therapeutics: List of Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Year and Type of Partnership
  • 10.3.4. Analysis by Company and Type of Partnership
  • 10.3.5. Analysis by Type of Technology Platform
  • 10.3.6. Analysis by Type of Partner
  • 10.3.7. Word Cloud Analysis: Emerging Focus Areas
  • 10.3.8. Analysis by Target Disease Indication(s)
  • 10.3.9. Analysis by Therapeutic Area
  • 10.3.10. Analysis by Therapeutic Area and Type of Partnership
  • 10.3.11. Most Active Players: Analysis by Number of Partnerships
  • 10.3.12. Regional Analysis
  • 10.3.13. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

• 11.1. Analysis Methodology and Key Parameters
• 11.2. Type of Funding
• 11.3. Exosome Therapeutics: List of Funding Instances
• 11.4. Analysis by Year of Funding
• 11.5. Analysis by Amount Invested
• 11.6. Analysis by Type of Funding
• 11.7. Analysis by Type of Funding and Amount Invested
• 11.8. Analysis by Year, Type of Funding and Amount Invested
• 11.9. Analysis by Purpose of Funding
• 11.10. Analysis by Target Disease Indication(s)
• 11.11. Analysis by Therapeutic Area
• 11.12. Most Active Players: Analysis by Number of Funding Instances
• 11.13. Most Active Players: Analysis by Amount Invested
• 11.14. Key Investors: Analysis by Number of Funding Instances
• 11.15. Regional Analysis
• 11.16. Summary of Funding Instances

12. START-UP HEALTH INDEXING

• 12.1. Analysis Methodology and Key Parameters
• 12.2. Analysis by Pipeline Maturity
• 12.3. Analysis by Pipeline Strength
• 12.4. Analysis by Financial Support
• 12.5. Analysis by Number of Investors
• 12.6. Analysis by Partnership Activity
• 12.7. Start-up Health Indexing: Roots Analysis Perspective

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

• 13.1. Chapter Overview
• 13.2. Exosome Development and Manufacturing Service Providers Landscape
  • 13.2.1. Analysis by Year of Establishment
  • 13.2.2. Analysis by Company Size
  • 13.2.3. Analysis by Location of Headquarters
  • 13.2.4. Analysis by Location of Headquarters and Company Size
• 13.3. Analysis by Type of Service(s) Offered
  • 13.3.1. Analysis by Method of Isolation
  • 13.3.2. Analysis by Method of Purification
  • 13.3.3. Analysis by Method of Characterization
  • 13.3.4. Analysis by Method of Exosome Manufacturing
  • 13.3.5. Analysis by Scale of Operation
  • 13.3.6. Analysis by Scalability

14. DRUG FAILURE ANALYSIS

• 14.1. Methodology and Key Parameters
• 14.2. Exosome Therapeutics: List of Failed Drug Candidates
  • 14.2.1. Analysis by Study Start Year and Year of Termination of the Clinical Trials
  • 14.2.2. Analysis by Trial Status of Discontinuation
  • 14.2.3. Analysis by Target Disease Indication(s)
  • 14.2.4. Analysis by Route of Administration
  • 14.2.5. Analysis by Type of Sponsor
  • 14.2.6. Analysis by Reasons for Drug Failure
  • 14.2.7. Word Cloud Analysis: Emerging Focus Area

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 15.1. Forecast Methodology and Key Assumptions
• 15.1. Global Exosome Therapeutics Market, 2027-2035
• 15.2. Global Exosome Therapeutics Market, 2027-2035: Distribution by Target Disease Indication(s)
  • 15.2.1. Exosome Therapeutics Market for COVID-19, 2027-2035
  • 15.2.2. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2027-2035
  • 15.2.3. Exosome Therapeutics Market for Retinitis Pigmentosa, 2027-2035
• 15.3. Global Exosome Therapeutics Market, 2027-2035: Distribution by Therapeutic Area
  • 15.3.1. Exosome Therapeutics Market for Infectious Diseases, 2027-2035
  • 15.3.2. Exosome Therapeutics Market for Ophthalmic Diseases, 2027-2035
  • 15.3.3. Exosome Therapeutics Market for Musculoskeletal Disorders, 2027-2035
• 15.4. Global Exosome Therapeutics Market, 2027-2035: Distribution by Route of Administration
  • 15.4.1. Intravenous Exosome Therapeutics Market, 2027-2035
  • 15.4.2. Intra-ocular Exosome Therapeutics Market, 2027-2035
  • 15.4.3. Intra-articular Exosome Therapeutics Market, 2027-2035
  • 15.4.4. Inhalation Exosome Therapeutics Market, 2027-2035
• 15.5. Global Exosome Therapeutics Market, 2027-2035: Distribution by Type of Formulation
  • 15.5.1. Exosome Therapeutics Market for Liquid Formulations, 2027-2035
  • 15.5.2. Exosome Therapeutics Market for Aerosol Formulations, 2027-2035
• 15.6. Global Exosome Therapeutics Market, 2027-2035: Distribution by Geography
  • 15.6.1. Exosome Therapeutics Market in North America, 2029-2035
  • 15.6.2. Exosome Therapeutics Market in Europe, 2027-2035
  • 15.6.3. Exosome Therapeutics Market in Asia Pacific, 2030-2035
• 15.7. Attractiveness and Competitiveness Matrix

16. EXECUTIVE INSIGHTS

• 16.1. Capricor Therapeutics
  • 16.1.1. Company Snapshot
  • 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
• 16.2. Exogenus Therapeutics
  • 16.2.1. Company Snapshot
  • 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
• 16.3. ILIAS Biologics
  • 16.3.1. Company Snapshot
  • 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

• Table 4.1 Exosome Therapeutics: Development Pipeline
• Table 4.2 Exosome Therapeutics: List of Developers
• Table 5.1 Codiak BioSciences: Product Portfolio
• Table 5.2 Codiak BioSciences: Clinical Trial Information
• Table 5.3 Recent Developments and Future Outlook
• Table 5.4 Coya Therapeutics: Product Portfolio
• Table 5.5 Recent Developments and Future Outlook
• Table 5.6 Curexsys: Product Portfolio
• Table 5.7 Recent Developments and Future Outlook
• Table 5.8 EV Therapeutics: Product Portfolio
• Table 5.9 Recent Developments and Future Outlook
• Table 5.10 Evox Therapeutics: Product Portfolio
• Table 5.11 Recent Developments and Future Outlook
• Table 5.12 SHIFTBIO: Product Portfolio
• Table 5.13 Recent Developments and Future Outlook
• Table 6.1 AGLE-102: Product Portfolio
• Table 6.2 AGLE-102: Clinical Trial Information
• Table 6.1 Ardoxso: Product Portfolio
• Table 6.2 Ardoxso: Clinical Trial Information
• Table 6.3 Recent Developments and Future Outlook
• Table 6.1 haMPC-Exos: Product Portfolio
• Table 6.2 haMPC-Exos: Clinical Trial Information
• Table 6.3 hMSC-Exos: Product Portfolio
• Table 6.4 hMSC-Exos: Clinical Trial Information
• Table 6.5 Undisclosed Drug 1: Product Portfolio
• Table 6.6 Undisclosed Drug 1: Clinical Trial Information
• Table 6.7 Recent Developments and Future Outlook
• Table 6.1 CovenD24: Product Portfolio
• Table 6.2 CovenD24: Clinical Trial Information
• Table 6.1 Undisclosed Drug 1: Product Portfolio
• Table 6.2 Undisclosed Drug 1: Clinical Trial Information
• Table 6.1 Recent Developments and Future Outlook
• Table 6.2 Undisclosed Drug 1: Product Portfolio
• Table 7.1 Exosome Therapeutics: List of Clinical Trials, 2017-2022
• Table 8.1 Exosome Therapeutics: List of Grants Awarded, Pre-2015-2022
• Table 9.1 Exosome Therapeutics: List of Global Events, 2017-2022
• Table 10.1 Exosome Therapeutics: List of Partnerships and Collaborations, 2017-2022
• Table 11.1 Exosome Therapeutics: List of Funding and Investment, 2017-2022
• Table 12.1 Exosome Therapeutics: List of Start-Ups, 2017-2022
• Table 13.1 Case Study: List of Exosome Service Providers
• Table 17.1 Exosome Therapeutics Market: Distribution by Phase of Development
• Table 17.2 Exosome Therapeutics Market: Distribution by Technology Platform
• Table 17.3 Exosome Therapeutics Market: Distribution by Type of Payload
• Table 17.4 Exosome Therapeutics Market: Distribution by Type of Formulation
• Table 17.5 Exosome Therapeutics Market: Distribution by Type of Therapy
• Table 17.6 Exosome Therapeutics Market: Distribution by Derived Source
• Table 17.7 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
• Table 17.8 Exosome Therapeutics Market: Distribution by Therapeutic Area
• Table 17.9 Exosome Therapeutics Market: Distribution by Phase of Development and
• Table 17.10 Exosome Therapeutics Market: Distribution by Route of Administration
• Table 17.11 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
• Table 17.12 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
• Table 17.13 Exosome Therapeutics Market: Distribution by Line of Treatment
• Table 17.14 Exosome Therapeutics Market: Distribution by Dosing Frequency
• Table 17.15 Exosome Therapeutics Developers: Distribution by Year of Establishment
• Table 17.16 Exosome Therapeutics Developers: Distribution by Company Size
• Table 17.17 Exosome Therapeutics Developers: Distribution by Location of Headquarters
• Table 17.18 Most Active Players: Distribution by Number of Exosome Therapeutics
• Table 17.19 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
• Table 17.20 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
• Table 17.21 Clinical Trials Analysis: Distribution by Trial Status
• Table 17.22 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre-2015- 2022
• Table 17.23 Clinical Trials Analysis: Distribution by Type of Sponsor / Collaborator
• Table 17.24 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
• Table 17.25 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
• Table 17.26 Clinical Trials Analysis: Distribution by Study Design
• Table 17.27 Clinical Trials Analysis: Distribution by Patient Enrollment
• Table 17.28 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
• Table 17.29 Clinical Trials Analysis: Distribution by Age Category
• Table 17.30 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
• Table 17.31 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
• Table 17.32 Most Active Industry Players: Distribution by Number of Registered Trials
• Table 17.33 Most Active Non-Industry Players: Distribution by Number of Registered Trials
• Table 17.34 Clinical Trials Analysis: Distribution by Trial Location
• Table 17.35 Clinical Trials Analysis: Distribution by Trial Status and Geography
• Table 17.36 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019 - 2022
• Table 17.37 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
• Table 17.38 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
• Table 17.39 Academic Grant Analysis: Analysis by Type of Funding Institute Center
• Table 17.40 Academic Grant Analysis: Distribution by Support Period
• Table 17.41 Academic Grant Analysis: Distribution by Purpose of Grants
• Table 17.42 Academic Grant Analysis: Distribution by Grant Activity Code
• Table 17.43 Academic Grant Analysis: Distribution by Local Recipients
• Table 17.44 Academic Grant Analysis: Distribution by Type of Recipient Organization
• Table 17.45 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
• Table 17.46 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
• Table 17.47 Academic Grant Analysis: Distribution by Study Section
• Table 17.48 Academic Grant Analysis: Distribution by Type of Grant Application
• Table 17.49 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
• Table 17.50 Global Events: Cumulative Half Yearly Trend, 2017-2022
• Table 17.51 Global Events: Distribution by Event Platform
• Table 17.52 Global Events: Distribution by Type of Event
• Table 17.53 Global Events: Distribution by Location of Event
• Table 17.54 Most Active Organizers: Distribution by Number of Events
• Table 17.55 Most Active Industry Participants: Distribution by Number of Events
• Table 17.56 Most Active Non-Industry Participants: Distribution by Number of Events
• Table 17.57 Global Events: Distribution by Designation of Participant
• Table 17.58 Global Events: Distribution by Affiliated Department of Participant
• Table 17.59 Most Active Speakers: Distribution by Number of Events
• Table 17.60 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
• Table 17.61 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 17.62 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
• Table 17.63 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
• Table 17.64 Partnerships and Collaborations: Distribution by Type of Technology Platform
• Table 17.65 Partnerships and Collaborations: Distribution by Type of Partner
• Table 17.66 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
• Table 17.67 Partnerships and Collaborations: Distribution by Therapeutic Area
• Table 17.68 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
• Table 17.69 Most Active Players: Distribution by Number of Partnerships
• Table 17.70 Partnerships and Collaborations: Regional Distribution
• Table 17.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
• Table 17.72 Funding and Investments: Year-wise Distribution by Year of Funding, 2017-2022
• Table 17.73 Funding and Investments: Year-wise Distribution by Amount Invested, 2017-2022 (till August)
• Table 17.74 Funding and Investments: Distribution by Type of Funding
• Table 17.75 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
• Table 17.76 Funding and Investments: Year-wise Distribution by Year, Type of Funding and Amount Invested, 2017- 2022
• Table 17.77 Funding and Investments: Distribution by Purpose of Funding
• Table 17.78 Funding and Investments: Distribution by Target Disease Indication(s)
• Table 17.79 Funding and Investments: Distribution by Therapeutic Area
• Table 17.80 Most Active Players: Distribution by Number of Funding Instances
• Table 17.81 Most Active Players: Distribution by Amount Invested (USD Million)
• Table 17.82 Key Investors: Distribution by Number of Funding Instances
• Table 17.83 Funding and Investments: Regional Distribution of Instances
• Table 17.84 Start-up Health Indexing: Distribution by Pipeline Maturity
• Table 17.85 Start-up Health Indexing: Distribution by Pipeline Strength
• Table 17.86 Start-up Health Indexing: Distribution by Financial Support
• Table 17.87 Start-up Health Indexing: Distribution by Partnership Activity
• Table 17.88 Case Study: Distribution of Exosome Service Providers by Year of Establishment
• Table 17.89 Case Study: Distribution of Exosome Service Providers by Company Size
• Table 17.90 Case Study: Distribution of Exosome Service Providers by Location of Headquarters
• Table 17.91 Case Study: Distribution of Exosome Service Providers by Location of Headquarters and Company Size
• Table 17.92 Case Study: Distribution of Exosome Service Providers by Type of Service(s) Offered
• Table 17.93 Case Study: Distribution of Exosome Service Providers by Method(s) of Isolation
• Table 17.94 Case Study: Distribution of Exosome Service Providers by Method(s) of Purification
• Table 17.95 Case Study: Distribution of Exosome Service Providers by Method(s) of Characterization
• Table 17.96 Case Study: Distribution of Exosome Service Providers by Method(s) of Exosome Manufacturing
• Table 17.97 Case Study: Distribution of Exosome Service Providers by Scale of Operation
• Table 17.98 Case Study: Distribution of Exosome Service Providers by Scalability
• Table 17.99 Drug Failure Analysis: Distribution by Study Start Year and Year of Termination of the Clinical Trials
• Table 17.100 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
• Table 17.101 Drug Failure Analysis: Distribution by Target Disease Indication(s)
• Table 17.102 Drug Failure Analysis: Distribution by Route of Administration
• Table 17.103 Drug Failure Analysis: Distribution by Type of Sponsor
• Table 17.104 Drug Failure Analysis: Distribution by Reasons for Drug Failure
• Table 17.105 Drug Failure Analysis: Other Plausible Reasons for Drug Failure
• Table 17.106 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Therapeutic Area (USD Million)
• Table 17.107 Exosome Therapeutics Market for Infectious Diseases, 2027-2035 (USD Million)
• Table 17.108 Exosome Therapeutics Market for Musculoskeletal Disorders, 2031-2035 (USD Million)
• Table 17.109 Exosome Therapeutics Market for Ophthalmic Diseases, 2033-2035 (USD Million)
• Table 17.110 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Route of Administration
• Table 17.111 Inhalation Exosome Therapeutics Market, 2027-2035 (USD Million)
• Table 17.112 Intravenous Exosome Therapeutics Market, 2031-2035 (USD Million)
• Table 17.113 Intra-articular Exosome Therapeutics Market, 2033-2035 (USD Million)
• Table 17.114 Intra-ocular Exosome Therapeutics Market, 2027-2035 (USD Million)
• Table 17.115 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Type of Formulation
• Table 17.116 Exosome Therapeutics Market for Liquid Formulations, 2027-2035 (USD Million)
• Table 17.117 Exosome Therapeutics Market for Aerosol Formulations, 2027-2035 (USD Million)
• Table 17.118 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Geography
• Table 17.119 Exosome Therapeutics Market in North America, 2029-2035 (USD Million)
• Table 17.120 Exosome Therapeutics Market in Europe, 2027-2035 (USD Million)
• Table 17.121 Exosome Therapeutics Market in Asia Pacific, 2030-2035 (USD Million)

LIST OF FIGURES

• Figure 3.1 Potential Sources of Exosomes
• Figure 3.2 Secretion of Exosomes
• Figure 3.3 Mechanism of Exosome Therapy
• Figure 4.1 Exosome Therapeutics Market: Distribution by Phase of Development
• Figure 4.2 Exosome Therapeutics Market: Distribution by Technology Platform
• Figure 4.3 Exosome Therapeutics Market: Distribution by Type of Payload
• Figure 4.4 Exosome Therapeutics Market: Distribution by Type of Formulation
• Figure 4.5 Exosome Therapeutics Market: Distribution by Type of Therapy
• Figure 4.6 Exosome Therapeutics Market: Distribution by Derived Source
• Figure 4.7 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
• Figure 4.8 Exosome Therapeutics Market: Distribution by Therapeutic Area
• Figure 4.9 Exosome Therapeutics Market: Distribution by Phase of Development and Therapeutic Area
• Figure 4.10 Exosome Therapeutics Market: Distribution by Route of Administration
• Figure 4.11 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
• Figure 4.12 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
• Figure 4.13 Exosome Therapeutics Market: Distribution by Line of Treatment
• Figure 4.14 Exosome Therapeutics Market: Distribution by Dosing Frequency
• Figure 4.15 Exosome Therapeutics Developers: Distribution by Year of Establishment
• Figure 4.16 Exosome Therapeutics Developers: Distribution by Company Size
• Figure 4.17 Exosome Therapeutics Developers: Distribution by Location of Headquarters
• Figure 4.18 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
• Figure 6.1 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
• Figure 6.2 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
• Figure 7.1 Clinical Trials Analysis: Distribution by Trial Status
• Figure 7.2 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre-2015- 2022
• Figure 7.3 Clinical Trials Analysis: Distribution by Type of Sponsor / Collaborator
• Figure 7.4 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
• Figure 7.5 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
• Figure 7.6 Clinical Trials Analysis: Distribution by Study Design
• Figure 7.7 Clinical Trials Analysis: Distribution by Patient Enrollment
• Figure 7.8 Clinical Trials Analysis: Year-wise Trend of Completed and Recruiting Trials
• Figure 7.9 Clinical Trials Analysis: Distribution by Age Group
• Figure 7.10 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
• Figure 7.11 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
• Figure 7.12 Most Active Industry Players: Distribution by Number of Registered Trials
• Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
• Figure 7.14 Clinical Trials Analysis: Distribution by Trial Location
• Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status and Geography
• Figure 8.1 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
• Figure 8.2 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
• Figure 8.3 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
• Figure 8.4 Academic Grant Analysis: Analysis by Type of Funding Institute Center
• Figure 8.5 Academic Grant Analysis: Distribution by Support Period
• Figure 8.6 Academic Grant Analysis: Distribution by Purpose of Grants
• Figure 8.7 Academic Grant Analysis: Distribution by Emerging Focus Area
• Figure 8.8 Academic Grant Analysis: Distribution by Grant Activity Code
• Figure 8.9 Academic Grant Analysis: Distribution by Local Recipients
• Figure 8.10 Academic Grant Analysis: Distribution by Type of Recipient Organization
• Figure 8.11 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded
• Figure 8.12 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
• Figure 8.13 Academic Grant Analysis: Distribution by Study Section
• Figure 8.14 Academic Grant Analysis: Distribution by Type of Grant Application
• Figure 8.15 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
• Figure 9.1 Global Events: Cumulative Half Yearly Trend, 2019-2022
• Figure 9.2 Global Events: Distribution by Event Platform
• Figure 9.3 Global Events: Distribution by Type of Event
• Figure 9.4 Global Events: Distribution by Location of Event
• Figure 9.5 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
• Figure 9.6 Most Active Organizers: Distribution by Number of Events
• Figure 9.7 Most Active Industry Participants: Distribution by Number of Events
• Figure 9.8 Most Active Non-Industry Participants: Distribution by Number of Events
• Figure 9.9 Global Events: Distribution by Designation of Participant
• Figure 9.10 Global Events: Distribution by Affiliated Department of Participant
• Figure 9.11 Most Active Speakers: Distribution by Number of Events
• Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
• Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 10.3 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
• Figure 10.4 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
• Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology Platform
• Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
• Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
• Figure 10.8 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
• Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
• Figure 10.10 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
• Figure 10.11 Most Active Players: Distribution by Number of Partnerships
• Figure 10.12 Partnerships and Collaborations: Regional Distribution
• Figure 10.13 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
• Figure 11.1 Funding and Investments: Year-wise Distribution by Year of Funding, 2017-2022
• Figure 11.2 Funding and Investments: Year-wise Distribution by Amount Invested, 2017-2022 (USD Million)
• Figure 11.3 Funding and Investments: Distribution by Type of Funding
• Figure 11.4 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
• Figure 11.5 Funding and Investments: Year-wise Distribution by Year, Type of Funding and Amount Invested, 2017- 2022
• Figure 11.6 Funding and Investments: Distribution by Purpose of Funding
• Figure 11.7 Funding and Investments: Distribution by Target Disease Indication(s)
• Figure 11.8 Funding and Investments: Distribution by Therapeutic Area
• Figure 11.9 Most Active Players: Distribution by Number of Funding Instances
• Figure 11.10 Most Active Players: Distribution by Amount Invested (USD Million)
• Figure 11.11 Key Investors: Distribution by Number of Funding Instances
• Figure 11.12 Funding and Investments: Distribution by Geographical Regions
• Figure 11.13 Summary of Funding Instances
• Figure 12.1 Start-up Health Indexing: Distribution by Pipeline Maturity
• Figure 12.2 Start-up Health Indexing: Distribution by Pipeline Strength
• Figure 12.3 Start-up Health Indexing: Distribution by Financial Support
• Figure 12.4 Start-up Health Indexing: Distribution by Number of Investors
• Figure 12.5 Start-up Health Indexing: Distribution by Partnership Activity
• Figure 12.6 Start-up Health Indexing: Roots Analysis Perspective
• Figure 13.1 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Year of Establishment
• Figure 13.2 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Company Size
• Figure 13.3 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters
• Figure 13.4 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters and Company Size
• Figure 13.5 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Type of Service(s) Offered
• Figure 13.6 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Isolation
• Figure 13.7 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Purification
• Figure 13.8 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Characterization
• Figure 13.9 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Manufacturing
• Figure 13.10 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scale of Operation
• Figure 13.11 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scalability
• Figure 14.1 Drug Failure Analysis: Distribution by Study Start Year and Year of Termination of the Clinical Trials
• Figure 14.2 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
• Figure 14.3 Drug Failure Analysis: Distribution by Target Disease Indication(s)
• Figure 14.4 Drug Failure Analysis: Distribution by Route of Administration
• Figure 14.5 Drug Failure Analysis: Distribution by Type of Sponsor
• Figure 14.6 Drug Failure Analysis: Distribution by Reasons for Drug Failure
• Figure 14.7 Word Cloud Analysis: Emerging Focus Area
• Figure 15.1 Global Exosome Therapeutics Market, 2027-2035 (USD Million)
• Figure 15.2 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Type of Target Disease Indication(s) (USD Million)
• Figure 15.3 Exosome Therapeutics Market for COVID-19, 2027-2035 (USD Million)
• Figure 15.4 Exosome Therapeutics Market for Retinitis Pigmentosa, 2027-2035 (USD Million)
• Figure 15.5 Exosome Therapeutics Market for Degenerative Meniscal Injury, 2027-2035 (USD Million)
• Figure 15.6 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Therapeutic Area (USD Million)
• Figure 15.7 Exosome Therapeutics Market for Infectious Diseases, 2027-2035 (USD Million)
• Figure 15.8 Exosome Therapeutics Market for Musculoskeletal Disorders, 2031-2035 (USD Million)
• Figure 15.9 Exosome Therapeutics Market for Ophthalmic Diseases, 2033-2035 (USD Million)
• Figure 15.10 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Route of Administration
• Figure 15.11 Inhalation Exosome Therapeutics Market, 2027-2035 (USD Million)
• Figure 15.12 Intravenous Exosome Therapeutics Market, 2031-2035 (USD Million)
• Figure 15.13 Intra-articular Exosome Therapeutics Market, 2033-2035 (USD Million)
• Figure 15.14 Intra-ocular Exosome Therapeutics Market, 2027-2035 (USD Million)
• Figure 15.15 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Type of Formulation
• Figure 15.16 Exosome Therapeutics Market for Liquid Formulations, 2027-2035 (USD Million)
• Figure 15.17 Exosome Therapeutics Market for Aerosol Formulations, 2027-2035 (USD Million)
• Figure 15.18 Global Exosome Therapeutics Market, 2027 and 2035: Distribution by Geography
• Figure 15.19 Exosome Therapeutics Market in North America, 2029-2035 (USD Million)
• Figure 15.20 Exosome Therapeutics Market in Europe, 2027-2035 (USD Million)
• Figure 15.21 Exosome Therapeutics Market in Asia Pacific, 2030-2035 (USD Million)